Sponsored by
The National Institute for Health and Care Excellence (NICE) has published final guidance approving vorasidenib (brand name Voranigo) for prescription on the NHS in England and Wales for people aged 12 and older with IDH-mutant low-grade gliomas, including astrocytoma and oligodendroglioma. The treatment will be made available through the Cancer Drugs Fund, offering faster access while routine NHS funding is established.
Vorasidenib, which received MHRA marketing authorization in October 2025, was shown in the INDIGO trial to slow tumor growth and delay the need for chemotherapy or radiotherapy, helping patients maintain quality of life for longer. NICE’s positive recommendation reflects both the clinical evidence and the strong support from patients, families, and charities advocating for access to this much-needed therapy. This is only the second new NHS-approved drug for brain tumors since temozolomide in 2006, marking a meaningful step forward for patients and families affected by low-grade gliomas.